Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Carolyn M. Jodka"'
Autor:
Odile E Levy, Carolyn M Jodka, Shijun Steven Ren, Lala Mamedova, Abhinandini Sharma, Manoj Samant, Lawrence J D'Souza, Christopher J Soares, Diane R Yuskin, Li Jenny Jin, David G Parkes, Krystyna Tatarkiewicz, Soumitra S Ghosh
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87704 (2014)
The design, synthesis and pharmacology of novel long-acting exenatide analogs for the treatment of metabolic diseases are described. These molecules display enhanced pharmacokinetic profile and potent glucoregulatory and weight lowering actions compa
Externí odkaz:
https://doaj.org/article/ab80028c3b224a48a0a7475a3371c5f3
Autor:
James L Trevaskis, Christine M Mack, Chengzao Sun, Christopher J Soares, Lawrence J D'Souza, Odile E Levy, Diane Y Lewis, Carolyn M Jodka, Krystyna Tatarkiewicz, Bronislava Gedulin, Swati Gupta, Carrie Wittmer, Michael Hanley, Bruce Forood, David G Parkes, Soumitra S Ghosh
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e78154 (2013)
Combination therapy is being increasingly used as a treatment paradigm for metabolic diseases such as diabetes and obesity. In the peptide therapeutics realm, recent work has highlighted the therapeutic potential of chimeric peptides that act on two
Externí odkaz:
https://doaj.org/article/45ac3705572548328d3eb17134e3c0a8
Autor:
David G. Parkes, M. G. W. Lu, Christine M. Mack, Jennifer Athanacio, Carolyn M. Jodka, J K Wilson, James M. Reynolds, K. Xu, Pamela A. Smith
Publikováno v:
Diabetes, Obesity and Metabolism. 13:1105-1113
Aims: Davalintide is a second-generation amylinomimetic peptide possessing enhanced pharmacological properties over rat amylin to reduce food intake in preclinical models. The current experiments in rats describe additional glucoregulatory actions of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bbfbb91a07b21519d91e6a748e9d18
https://doi.org/10.1111/j.1463-1326.2011.01465.x
https://doi.org/10.1111/j.1463-1326.2011.01465.x
Autor:
Holly Maier, Carolyn M. Jodka, David G. Parkes, Christian Weyer, Jennifer Athanacio, Jonathan D. Roth, Christine M. Mack, Todd Coffey
Publikováno v:
Endocrinology. 148:6054-6061
Circulating levels of the pancreatic β-cell peptide hormone amylin and the gut peptide PYY[3–36] increase after nutrient ingestion. Both have been implicated as short-term signals of meal termination with anorexigenic and weight-reducing effects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b10d4488d5373b6cbb61b5690bb7852
https://doi.org/10.1210/en.2007-0898
https://doi.org/10.1210/en.2007-0898
Autor:
Julie A. Hoyt, Carolyn M. Jodka, Bronislava Gedulin, David G. Parkes, Eric S. Kendall, Pamela A. Smith, A. Lwin, Christen M. Anderson, Kevin McCowen, Diane M. Hargrove, Shawn D. Flanagan, John Patrick Herich, James M. Reynolds
Publikováno v:
Regulatory Peptides. 141:113-119
Exenatide, the active ingredient of BYETTA (exenatide injection), is an incretin mimetic that has been developed for the treatment of patients with type 2 diabetes. Exenatide binds to and activates the known GLP-1 receptor with a potency comparable t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cbaf5f430d29160028a2422ef198146
https://doi.org/10.1016/j.regpep.2006.12.021
https://doi.org/10.1016/j.regpep.2006.12.021
Autor:
J L Roan, Kevin D. Laugero, Calvin Vu, Christine M. Mack, Sunil Bhavsar, David G. Parkes, Andrew A. Young, Julie A. Hoyt, Candace X. Moore, J K Wilson, Carolyn M. Jodka
Publikováno v:
International Journal of Obesity. 30:1332-1340
Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents.To mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5edc6eab414283f6dfb7a0f116cff2
https://doi.org/10.1038/sj.ijo.0803284
https://doi.org/10.1038/sj.ijo.0803284
Autor:
Carolyn M. Jodka, Kevin D. Laugero, Christine M. Mack, Que Liu, Andrew A. Young, David G. Parkes
Publikováno v:
Drug Development Research. 67:553-558
Exenatide (exendin-4) is an incretin mimetic peptide that shares several glucoregulatory actions with the endogenous incretin GLP-1. In addition to its actions on glucose control, exenatide produces effects to reduce food intake and body weight in al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f63af1044b354488837315203c9a21f7
https://doi.org/10.1002/ddr.20121
https://doi.org/10.1002/ddr.20121
Publikováno v:
Regulatory Peptides. 130:19-26
Background and aims The neuroendocrine hormone amylin, cosecreted with insulin from pancreatic β-cells in response to nutrient ingestion, has several physiologic actions to limit the rate of nutrient uptake, including the slowing of gastric emptying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0dcff06b3ed2c48e1c2a97065cf52a3
https://doi.org/10.1016/j.regpep.2005.02.010
https://doi.org/10.1016/j.regpep.2005.02.010
Autor:
B. R. Gedulin, Ved Srivastava, Sunil Bhavsar, Andrew A. Young, Pamela A. Smith, David G. Parkes, Carolyn M. Jodka, Candace X. Moore, Richard A. Pittner, James R. Paterniti
Publikováno v:
International Journal of Obesity. 28:963-971
BACKGROUND: Peptide YY (PYY) is a 36 amino-acid peptide secreted from ileal L cells following meals. The cleaved subpeptide PYY[3–36] is biologically active and may constitute the majority of circulating PYY-like immunoreactivity. The peptide famil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be9147ee46bea897a10bf040c2f057d6
https://doi.org/10.1038/sj.ijo.0802696
https://doi.org/10.1038/sj.ijo.0802696
Autor:
David G. Parkes, José Marco, Ramona A. Silvestre, Jovita Rodrı́guez-Gallardo, Andrew A. Young, Richard A. Pittner, Carolyn M. Jodka
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 280:E443-E449
Amylin, a peptide hormone from pancreatic β-cells, is reported to inhibit insulin secretion in vitro and in vivo and to inhibit nutrient-stimulated glucagon secretion in vivo. However, it has been reported not to affect arginine-stimulated glucagon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ef00cd19926572c54a81b41261f97cd
https://doi.org/10.1152/ajpendo.2001.280.3.e443
https://doi.org/10.1152/ajpendo.2001.280.3.e443